Arwa Z Alromaih1, Abdullah I Almater1, Abdulrahman F Albloushi1, Norah F Alkheraiji1, Ahmed M Abu El-Asrar2,3. 1. Department of Ophthalmology, College of Medicine, King Saud University, Old Airport Road, P.O. Box 245, Riyadh, 11411, Saudi Arabia. 2. Department of Ophthalmology, College of Medicine, King Saud University, Old Airport Road, P.O. Box 245, Riyadh, 11411, Saudi Arabia. abuasrar@KSU.edu.sa. 3. College of Medicine, Dr. Nasser Al-Rashid Research Chair in Ophthalmology, King Saud University, Riyadh, Saudi Arabia. abuasrar@KSU.edu.sa.
Abstract
PURPOSE: To investigate the outcomes of initial-onset acute uveitis associated with Vogt-Koyanagi-Harada (VKH) disease that occurred during pregnancy. METHODS: This is a retrospective case series. RESULTS: During the period between January 2001 and December 2021, we identified 112 patients with initial-onset acute uveitis associated with VKH disease, 67 (59.8%) were females. Among the female patients, 10 (14.9%) patients (20 eyes) were pregnant. Of these patients, 5 patients presented in the first trimester, 3 in the second trimester and 2 in the third trimester. The follow-up period ranged from 8 to 108 months (mean 35.2 ± 28.3 months). At presentation, 8 (80%) patients had initial-onset acute VKH disease with anterior segment (AS) inflammation and 2 (20%) initial-onset acute VKH disease without AS inflammation. All patients were initially treated with systemic corticosteroids combined with cyclosporine. During follow-up period, none of the patients with initial-onset acute VKH disease without AS inflammation developed any complications. Complications including "sunset glow fundus" in 8 (40%) eyes, cataract in 2 (10%) eyes and subretinal fibrosis in 1 (5%) eye were recorded in patients with initial-onset acute VKH disease with AS inflammation. Four (40%) patients developed pregnancy-related complications, including abortion in 1 patient, systemic hypertension in 1 patient and premature rupture of membrane in 2 patients. There were no documented congenital anomalies in all born babies. Best-corrected visual acuity of ≥ 20/20 was achieved in 16 (80%) eyes at the final follow-up. CONCLUSION: Primary treatment with combined systemic corticosteroids and cyclosporine in initial-onset acute uveitis associated with VKH disease was safe and effective.
PURPOSE: To investigate the outcomes of initial-onset acute uveitis associated with Vogt-Koyanagi-Harada (VKH) disease that occurred during pregnancy. METHODS: This is a retrospective case series. RESULTS: During the period between January 2001 and December 2021, we identified 112 patients with initial-onset acute uveitis associated with VKH disease, 67 (59.8%) were females. Among the female patients, 10 (14.9%) patients (20 eyes) were pregnant. Of these patients, 5 patients presented in the first trimester, 3 in the second trimester and 2 in the third trimester. The follow-up period ranged from 8 to 108 months (mean 35.2 ± 28.3 months). At presentation, 8 (80%) patients had initial-onset acute VKH disease with anterior segment (AS) inflammation and 2 (20%) initial-onset acute VKH disease without AS inflammation. All patients were initially treated with systemic corticosteroids combined with cyclosporine. During follow-up period, none of the patients with initial-onset acute VKH disease without AS inflammation developed any complications. Complications including "sunset glow fundus" in 8 (40%) eyes, cataract in 2 (10%) eyes and subretinal fibrosis in 1 (5%) eye were recorded in patients with initial-onset acute VKH disease with AS inflammation. Four (40%) patients developed pregnancy-related complications, including abortion in 1 patient, systemic hypertension in 1 patient and premature rupture of membrane in 2 patients. There were no documented congenital anomalies in all born babies. Best-corrected visual acuity of ≥ 20/20 was achieved in 16 (80%) eyes at the final follow-up. CONCLUSION: Primary treatment with combined systemic corticosteroids and cyclosporine in initial-onset acute uveitis associated with VKH disease was safe and effective.
Authors: Ahmed M Abu El-Asrar; Nele Berghmans; Saleh A Al-Obeidan; Ahmed Mousa; Ghislain Opdenakker; Jo Van Damme; Sofie Struyf Journal: Invest Ophthalmol Vis Sci Date: 2016-09-01 Impact factor: 4.799
Authors: Ahmed M Abu El-Asrar; Sofie Struyf; Dustan Kangave; Saleh S Al-Obeidan; Ghislain Opdenakker; Karel Geboes; Jo Van Damme Journal: Clin Immunol Date: 2011-01-31 Impact factor: 3.969
Authors: Ahmed M Abu El-Asrar; Mamdouh Al Tamimi; Suhail Hemachandran; Hani S Al-Mezaine; Abdulrahman Al-Muammar; Dustan Kangave Journal: Acta Ophthalmol Date: 2013-04-10 Impact factor: 3.761